Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
90Quote
Valuation & Ratios
Returns & Efficiency
Social Signal Score
Earnings
Thu, Oct 29(in 2 months)
Consensus estimate $-0.96 per share
Typical surprise -23.8% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Aug 14$-1.31 vs $-0.88miss
- Fri, May 15$-1.05 vs $-0.85miss
- Thu, Mar 12$-0.83 vs $-0.80miss
- Thu, Oct 30$-1.00 vs $-0.50miss
- Thu, Aug 14$0.50 vs $-2.25beat
- Fri, May 30$-29.75 vs $-6.20miss
Estimates and results for CNSY via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
CNSYhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (2)
- Newszacks.com·20h ago·Negative
Cerenome (CNSY) Reports Q2 Loss, Misses Revenue Estimates Cerenome (CNSY) came out with a quarterly loss of $1.31 per share versus the Zacks Consensus Estimate of a loss of $0.96. This compares to a loss of $0.25 per share a year ago.
View source ↗ - Newsglobenewswire.com·22h ago·Neutral
Cerenome Reports Second Quarter 2026 Financial Results and Business Update HOUSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company"), a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence, today announced financial results for the second quarter ended June 30, 2026, and provided an overview of recent and upcoming business highlights.
View source ↗